Kevin Parker is the CEO and co-founder of Cartography Biosciences. Cartography Biosciences is building a differentiated oncology pipeline of antibody-based therapies designed to target tumors more precisely than existing therapeutics. At Cartography, he leads a team dedicated to identifying novel cancer targets and developing therapies with the greatest patient impact; and outside of Cartography, Kevin is an avid rock climber.

Kevin’s scientific background is in genomics, cancer biology, and computational biology, with a focus on developing novel genomics methods to better understand and treat disease. Kevin holds a Ph.D. from Stanford University and a B.A. in Human Developmental and Regenerative Biology from Harvard University.

Targeted cytotoxic therapies in oncology, such as T-cell engagers, antibody drug conjugates, CAR-T therapies, and radioligand therapies, rely on specific targeting of cells of interest – reaching malignant cells in tumors but sparing healthy cells across the body. On-target, off-tumor toxicity poses a significant challenge in developing safe, effective antibody therapeutics. Single-cell genomic profiling enables improved precision in target selection by revealing tissue-specific expression patterns across healthy and malignant cells.

Cartography has developed the ATLAS and SUMMIT platforms that systematically evaluate therapeutic windows using genome-wide, single-cell expression data across tens of millions of cells from thousands of healthy and tumor tissue samples. ATLAS identifies optimal single targets, while SUMMIT analyzes combinatorial target pairs for enhanced specificity and reduced off-tumor effects.

This talk will focus on how these platforms identified LY6G6D as a promising target with minimal healthy tissue expression, leading to successful optimization of CB21, a T-cell engager now advancing through clinical development. ATLAS and SUMMIT enable systematic target prioritization and inform antibody design across diverse oncology indications, supporting the development of therapeutics with improved therapeutic windows.